197 related articles for article (PubMed ID: 12936997)
1. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge.
Roy CJ; Baker R; Washburn K; Bray M
Antimicrob Agents Chemother; 2003 Sep; 47(9):2933-7. PubMed ID: 12936997
[TBL] [Abstract][Full Text] [Related]
2. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir.
Bray M; Martinez M; Kefauver D; West M; Roy C
Antiviral Res; 2002 Jun; 54(3):129-42. PubMed ID: 12062386
[TBL] [Abstract][Full Text] [Related]
3. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir.
Smee DF; Bailey KW; Wong M; Sidwell RW
Antiviral Res; 2000 Sep; 47(3):171-7. PubMed ID: 10974369
[TBL] [Abstract][Full Text] [Related]
4. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge.
Bray M; Martinez M; Smee DF; Kefauver D; Thompson E; Huggins JW
J Infect Dis; 2000 Jan; 181(1):10-9. PubMed ID: 10608745
[TBL] [Abstract][Full Text] [Related]
5. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir.
Smee DF; Bailey KW; Sidwell RW
Antivir Chem Chemother; 2000 Jul; 11(4):303-9. PubMed ID: 10950392
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice.
Smee DF; Bailey KW; Sidwell RW
Chemotherapy; 2003 Jun; 49(3):126-31. PubMed ID: 12815205
[TBL] [Abstract][Full Text] [Related]
7. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir.
Smee DF; Bailey KW; Sidwell RW
Antivir Chem Chemother; 2001 Jan; 12(1):71-6. PubMed ID: 11437324
[TBL] [Abstract][Full Text] [Related]
8. Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment.
Smee DF; Gowen BB; Wandersee MK; Wong MH; Skirpstunas RT; Baldwin TJ; Hoopes JD; Sidwell RW
Int J Antimicrob Agents; 2008 Apr; 31(4):352-9. PubMed ID: 18206353
[TBL] [Abstract][Full Text] [Related]
9. Antiviral prophylaxis of smallpox.
Bray M; Roy CJ
J Antimicrob Chemother; 2004 Jul; 54(1):1-5. PubMed ID: 15163655
[TBL] [Abstract][Full Text] [Related]
10. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice.
Smee DF; Bailey KW; Wong MH; Sidwell RW
Antiviral Res; 2001 Oct; 52(1):55-62. PubMed ID: 11530188
[TBL] [Abstract][Full Text] [Related]
11. Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug.
Smee DF; Bailey KW; Sidwell RW
Antiviral Res; 2002 May; 54(2):113-20. PubMed ID: 12062396
[TBL] [Abstract][Full Text] [Related]
12. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.
Smee DF; Sidwell RW; Kefauver D; Bray M; Huggins JW
Antimicrob Agents Chemother; 2002 May; 46(5):1329-35. PubMed ID: 11959564
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice.
Quenelle DC; Collins DJ; Kern ER
Antimicrob Agents Chemother; 2003 Oct; 47(10):3275-80. PubMed ID: 14506041
[TBL] [Abstract][Full Text] [Related]
14. Cidofovir in the treatment of poxvirus infections.
De Clercq E
Antiviral Res; 2002 Jul; 55(1):1-13. PubMed ID: 12076747
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats.
Cundy KC; Bidgood AM; Lynch G; Shaw JP; Griffin L; Lee WA
Drug Metab Dispos; 1996 Jul; 24(7):745-52. PubMed ID: 8818571
[TBL] [Abstract][Full Text] [Related]
16. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.
Quenelle DC; Collins DJ; Wan WB; Beadle JR; Hostetler KY; Kern ER
Antimicrob Agents Chemother; 2004 Feb; 48(2):404-12. PubMed ID: 14742188
[TBL] [Abstract][Full Text] [Related]
17. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.
Ciesla SL; Trahan J; Wan WB; Beadle JR; Aldern KA; Painter GR; Hostetler KY
Antiviral Res; 2003 Aug; 59(3):163-71. PubMed ID: 12927306
[TBL] [Abstract][Full Text] [Related]
18. Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits.
Cundy KC; Lynch G; Shaw JP; Hitchcock MJ; Lee WA
Curr Eye Res; 1996 May; 15(5):569-76. PubMed ID: 8670758
[TBL] [Abstract][Full Text] [Related]
19. In vivo imaging of cidofovir treatment of cowpox virus infection.
Goff A; Twenhafel N; Garrison A; Mucker E; Lawler J; Paragas J
Virus Res; 2007 Sep; 128(1-2):88-98. PubMed ID: 17524511
[TBL] [Abstract][Full Text] [Related]
20. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.
Lalezari JP; Drew WL; Glutzer E; James C; Miner D; Flaherty J; Fisher PE; Cundy K; Hannigan J; Martin JC
J Infect Dis; 1995 Apr; 171(4):788-96. PubMed ID: 7706804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
